시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 비식별처리 건강 데이터 시장 보고서(2025년)
De-Identified Health Data Global Market Report 2025
상품코드 : 1855848
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,693,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,675,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,656,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

비식별처리 건강 데이터 시장 규모는 최근 급속도로 확대되고 있습니다. 2024년 82억 달러에서 2025년에는 92억 달러에 달하고, CAGR 12.2%로 확대될 전망입니다. 이 실적기간 내 성장은 전자기술의 보급, 환자 데이터 프라이버시에 대한 의식 증가, 헬스케어 애널리틱스의 이용 확대, 집단 건강 관리 연구의 확대, 의료 정보 기술 시스템의 성장, 임상시험에서의 데이터 활용 증가 등에 의해 발생하였습니다.

비식별처리 건강 데이터 시장 규모는 향후 수년간 급성장할 것으로 예측됩니다. 2029년에는 CAGR 11.8%로 144억 달러로 성장할 전망입니다. 예측 기간 동안 성장의 원동력은 건강 관리에서 인공지능의 응용 확대, 의약품 개발에서 실제 세계 증거에 대한 수요 증가, 건강 데이터의 2차 이용에 대한 주목 증가, 프라이버시 향상 기술에 대한 수요 증가, 정밀의료에 대한 요구 증가입니다. 예측 기간의 주요 동향으로는 데이터 프라이버시 프로토콜 개발, 머신러닝 파이프라인 구축, 전자 의료 기록과의 통합, 집단 건강 플랫폼과의 통합, 데이터 익명화 기술의 혁신 등이 있습니다.

전자 차트의 채택 확대가 향후 수년간 비식별처리 건강 데이터 시장의 확대를 지원할 것으로 예측됩니다. 전자 의료 기록은 진단, 치료, 투약, 검사 결과 및 기타 건강 관련 정보를 포함한 환자의 완전한 병력을 디지털화한 것으로, 권한이 부여된 의료 전문가가 안전하게 보관하고 액세스할 수 있습니다. 전자 의료 기록의 사용이 증가하고 있는 배경에는 종합적인 임상 데이터에 정확하고 실시간으로 액세스함으로써 환자의 케어와 안전성을 향상시킬 수 있는 장점이 있습니다. 비식별처리 건강 데이터는 환자의 프라이버시를 보장하면서 안전한 데이터 공유 및 고급 분석의 적용을 가능하게 함으로써 전자 의료 기록의 기능을 강화합니다. 이는 더 나은 임상 결정을 지원하고 건강 관리 성과를 향상시키는 데 기여합니다. 예를 들어, 2022년 6월 영국에 본부를 둔 정부 부문인 보건사회의료부는 2025년 3월까지 모든 NHS 트러스트가 전자 의료 기록을 도입했다고 밝혔으며, 2023년 12월 도입률 90%에서 상승했다고 보고했습니다. 따라서, 전자 차트의 이용 확대가 비식별처리 건강 데이터 시장의 확대에 기여하고 있습니다.

비식별처리 건강 데이터 시장의 주요 기업은 데이터 중심의 건강 관리 의사 결정을 지원하기 위해 실세계 바이오마커 커버리지 애플리케이션과 같은 신기술을 개발하고 있습니다. 실세계 바이오마커 커버리지 애플리케이션은 비식별처리된 환자 데이터를 사용하여 관리된 임상 환경 이외의 다양한 집단에서 바이오마커의 동향과 그 효과를 모니터링하고 평가합니다. 이를 통해 건강 관리 제공업체와 연구자는 치료 결과와 질병 패턴에 대한 귀중한 인사이트를 얻을 수 있습니다. 예를 들어, 2025년 7월 미국에 본사를 두고 있는 의료 기술 기업인 Datma Inc.는 제약 팀이 Datma의 데이터 제공업체 네트워크 내에서 실제 세계의 바이오마커 커버리지를 신속하게 평가하는 것을 목표로 하는 무료 애플리케이션 Federated Biomarker Explorer를 발표했습니다. 이 도구는 바이오마커 분포에 대한 코호트 수준의 인사이트를 제공하여 계약이나 기술 지원 없이 데이터의 가용성을 평가할 수 있습니다. 또한 사용자 자신의 데이터 세트를 안전하게 통합하고 비교할 수 있으며 임상 및 인구통계학적 필터를 적용하여 필요한 환자 집단이 있는지 확인한 후 연구를 진행함으로써 조기 실현 가능성 평가를 지원합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

De-identified health data refers to patient information from which all personally identifiable details, such as names, addresses, and social security numbers, have been removed, making it impossible to trace the data back to any individual. It enables healthcare providers, researchers, and organizations to analyze trends, improve treatments, and develop effective public health strategies while maintaining patient privacy.

The primary types of de-identified health data include clinical data, genomic data, patient demographics, prescription data, hospital and provider data, and pharmacogenomic data. Clinical data consists of health-related information collected during healthcare delivery, including medical history, diagnoses, treatments, laboratory results, and outcomes. This data is applied across multiple areas, including clinical research and trials, public health, precision medicine, health economics and outcomes research (HEOR), population health management, drug discovery and development, healthcare quality improvement, insurance underwriting and risk assessment, and more. Key end users include pharmaceutical companies, biotechnology firms, healthcare providers, insurance companies and payers, research institutions, government agencies, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The de-identified health data market research report is one of a series of new reports from The Business Research Company that provides de-identified health data market statistics, including de-identified health data industry global market size, regional shares, competitors with a de-identified health data market share, detailed de-identified health data market segments, market trends and opportunities, and any further data you may need to thrive in the de-identified health data industry. This de-identified health data market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The de-identified health data market size has grown rapidly in recent years. It will grow from $8.20 billion in 2024 to $9.20 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth during the historic period is attributed to the increasing adoption of electronic health records, rising awareness of patient data privacy, greater use of healthcare analytics, expanding research in population health management, growth of health information technology systems, and increased utilization of data in clinical trials.

The de-identified health data market size is expected to see rapid growth in the next few years. It will grow to $14.40 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth during the forecast period is driven by the expanding application of artificial intelligence in healthcare, rising demand for real-world evidence in drug development, growing focus on the secondary use of health data, increasing demand for privacy-enhancing technologies, and the rising need for precision medicine. Key trends in the forecast period include the development of data privacy protocols, creation of machine learning pipelines, integration with electronic health records, incorporation with population health platforms, and innovations in data anonymization techniques.

The growing adoption of electronic health records is expected to support the expansion of the de-identified health data market in the coming years. Electronic health records refer to digital versions of patients' complete medical histories, including diagnoses, treatments, medications, laboratory results, and other health-related information that are securely stored and accessible by authorized healthcare professionals. The increasing use of electronic health records is driven by their ability to improve patient care and safety through accurate and real-time access to comprehensive clinical data. De-identified health data enhances the functionality of electronic health records by enabling secure data sharing and the application of advanced analytics while ensuring patient privacy. This supports better clinical decision-making and contributes to improved healthcare outcomes. For example, in June 2022, the Department of Health and Social Care, a government department based in the United Kingdom, reported that all NHS trusts are expected to implement electronic health records by March 2025, up from a ninety percent adoption rate in December 2023. As a result, the growing use of electronic health records is contributing to the expansion of the de-identified health data market.

Key companies in the de-identified health data market are developing new technologies such as real-world biomarker coverage applications to support data-driven healthcare decision-making. A real-world biomarker coverage application uses de-identified patient data to monitor and evaluate biomarker trends and their effectiveness in varied populations outside of controlled clinical environments. This enables healthcare providers and researchers to gain valuable insights into treatment outcomes and disease patterns. For instance, in July 2025, Datma Inc., a healthcare technology company based in the United States, introduced the Federated Biomarker Explorer, a free application intended for pharmaceutical teams to rapidly assess real-world biomarker coverage within Datma's network of data contributors. This tool offers cohort-level insights into biomarker distribution and allows teams to evaluate data availability without entering contracts or requiring technical support. It also enables secure integration of users' own datasets for comparison and supports early feasibility assessments by applying clinical and demographic filters to confirm the presence of needed patient populations before proceeding with studies.

In July 2025, Datavant Inc., a health information technology company based in the United States, acquired Aetion Inc. for an undisclosed amount. This acquisition is aimed at strengthening Datavant's capabilities in real-world evidence by incorporating Aetion's advanced analytics platform. The integration is intended to offer healthcare and life sciences organizations a comprehensive solution for producing high-quality, regulatory-grade insights using de-identified health data. Aetion Inc. is a real-world evidence platform also based in the United States, known for providing de-identified health data solutions through tools such as Aetion Generate.

Major players in the de-identified health data market are UnitedHealth Group Incorporated, Oracle Corporation, IQVIA Holdings Inc, ICON Public Limited Company, Datavant Inc, Premier Inc., iMerit Technology Services Pvt. Ltd., Tempus Labs Inc., Medidata Solutions Inc., Veradigm Inc., Flatiron Health, Merative LP, Komodo Health Inc., Shaip Inc., Truveta Inc., Evidation Health Inc., TriNetX Inc., Clarify Health Solutions Inc., Akrivia Health Ltd., Gradient Health Inc.

North America was the largest region in the de-identified health data market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in de-identified health data report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the de-identified health data market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The de-identified health data market includes revenues earned by entities by providing services such as medical research and clinical studies, machine learning development, public health and epidemiology, healthcare system improvement, and health economics and policy planning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

De-Identified Health Data Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on de-identified health data market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for de-identified health data ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The de-identified health data market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. De-Identified Health Data Market Characteristics

3. De-Identified Health Data Market Trends And Strategies

4. De-Identified Health Data Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global De-Identified Health Data Growth Analysis And Strategic Analysis Framework

6. De-Identified Health Data Market Segmentation

7. De-Identified Health Data Market Regional And Country Analysis

8. Asia-Pacific De-Identified Health Data Market

9. China De-Identified Health Data Market

10. India De-Identified Health Data Market

11. Japan De-Identified Health Data Market

12. Australia De-Identified Health Data Market

13. Indonesia De-Identified Health Data Market

14. South Korea De-Identified Health Data Market

15. Western Europe De-Identified Health Data Market

16. UK De-Identified Health Data Market

17. Germany De-Identified Health Data Market

18. France De-Identified Health Data Market

19. Italy De-Identified Health Data Market

20. Spain De-Identified Health Data Market

21. Eastern Europe De-Identified Health Data Market

22. Russia De-Identified Health Data Market

23. North America De-Identified Health Data Market

24. USA De-Identified Health Data Market

25. Canada De-Identified Health Data Market

26. South America De-Identified Health Data Market

27. Brazil De-Identified Health Data Market

28. Middle East De-Identified Health Data Market

29. Africa De-Identified Health Data Market

30. De-Identified Health Data Market Competitive Landscape And Company Profiles

31. De-Identified Health Data Market Other Major And Innovative Companies

32. Global De-Identified Health Data Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The De-Identified Health Data Market

34. Recent Developments In The De-Identified Health Data Market

35. De-Identified Health Data Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기